Recent News

• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.07.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
• 03.05.2025 - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
• 02.18.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2025 - Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2025 - Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

Recent Filings

• 03.06.2025 - SC TO-C Written communication relating to an issuer or third party
• 03.05.2025 - SC14D9C Written communication relating to third party tender offer
• 03.05.2025 - 8-K/A Current report
• 03.05.2025 - SC TO-C Written communication relating to an issuer or third party
• 03.05.2025 - SC14D9C Written communication relating to third party tender offer
• 03.05.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 8-K Current report